Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

SHA:688163 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	199.6	196.21	194.92	190.13	174.21	207.5
Other Revenue	-	-	-	0.02	0.01	1.19
Revenue	199.6	196.21	194.92	190.14	174.22	208.69
Revenue Growth	0.97%	0.66%	2.51%	9.14%	-16.52%	12.46%
Cost of Revenue	44.27	45	45.8	49.84	33.5	36.33
Gross Profit	155.33	151.2	149.11	140.3	140.72	172.36
Selling, General & Admin	74.73	77.46	76.71	74.35	73.71	62.81
Research & Development	21.71	19.51	23.84	30.41	15.46	25.76
Other Operating Expenses	2.53	1.88	1.68	1.53	1.21	1.45
Operating Expenses	95.72	98.95	102.96	107.08	90.28	90.34
Operating Income	59.6	52.25	46.15	33.22	50.45	82.03
Interest Expense	-0.1	-0.18	-0.43	-0.65	-0.68	-0.71
Interest & Investment Income	10.37	10.79	6.12	10.62	16.3	1.48
Currency Exchange Gain (Loss)	-0.2	-0.08	-0.03	0.12	0.49	-0.12
Other Non Operating Income (Expenses)	-2.79	-0.2	0.23	-0.25	0.42	-0.3
EBT Excluding Unusual Items	66.88	62.59	52.04	43.06	66.97	82.38
Gain (Loss) on Sale of Investments	1.57	1.41	-4.97	2.59	2.62	-0.79
Gain (Loss) on Sale of Assets	0	0.02	0.41	-0.01	-0.07	-0.25
Asset Writedown	-2.16	-	-	-	-	-
Other Unusual Items	0.1	0.19	3.09	-0.23	4.53	6.54
Pretax Income	66.4	64.21	50.57	45.42	74.04	87.88
Income Tax Expense	11.94	12.42	6.28	6.64	9.84	11.39
Earnings From Continuing Operations	54.46	51.79	44.29	38.77	64.2	76.48
Net Income	54.46	51.79	44.29	38.77	64.2	76.48
Net Income to Common	54.46	51.79	44.29	38.77	64.2	76.48
Net Income Growth	21.14%	16.93%	14.23%	-39.60%	-16.06%	21.07%
Shares Outstanding (Basic)	107	108	108	108	102	81
Shares Outstanding (Diluted)	107	108	108	108	102	81
Shares Change	-2.01%	-0.13%	0.30%	5.70%	25.24%	0.46%
EPS (Basic)	0.51	0.48	0.41	0.36	0.63	0.94
EPS (Diluted)	0.51	0.48	0.41	0.36	0.63	0.94
EPS Growth	23.62%	17.07%	13.89%	-42.86%	-32.98%	20.51%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	23.06	0.93	-9.12	4.15	41.46	64.68
Free Cash Flow Per Share	0.22	0.01	-0.08	0.04	0.41	0.80
Dividend Per Share	0.260	0.380	0.320	0.200	0.750	0.900
Dividend Growth	-18.75%	18.75%	60.00%	-73.33%	-16.67%	-
Gross Margin	77.82%	77.06%	76.50%	73.79%	80.77%	82.59%
Operating Margin	29.86%	26.63%	23.68%	17.47%	28.96%	39.30%
Profit Margin	27.29%	26.39%	22.72%	20.39%	36.85%	36.65%
Free Cash Flow Margin	11.55%	0.47%	-4.68%	2.18%	23.79%	30.99%
EBITDA	80.28	70.85	65.64	49.46	64.43	96.15
EBITDA Margin	40.22%	36.11%	33.67%	26.01%	36.98%	46.07%
D&A For EBITDA	20.68	18.6	19.49	16.24	13.98	14.12
EBIT	59.6	52.25	46.15	33.22	50.45	82.03
EBIT Margin	29.86%	26.63%	23.68%	17.47%	28.96%	39.30%
Effective Tax Rate	17.98%	19.34%	12.41%	14.62%	13.29%	12.97%
Revenue as Reported	95.39	196.21	194.92	190.14	174.22	208.69
Advertising Expenses	-	22.6	21.26	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error